脳卒中エキスパート 降圧療法を究める

出版社: 中外医学社
著者:
発行日: 2020-11-20
分野: 臨床医学:内科  >  脳神経科学/神経内科学
ISBN: 9784498328624
電子書籍版: 2020-11-20 (1版1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

3,960 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,960 円(税込)

商品紹介

脳卒中診療における特に重要なテーマについて,各領域の専門家がテーマ毎に1冊で理解できるように詳説するシリーズ最新刊.降圧療法に焦点を合わせ,脳卒中治療における血圧管理を新しいガイドラインに即して解説.これまでエビデンスのなかった無症候性脳血管病変や,認知症との関連についても言及.治療や予防にあたって最良の選択をするため,必須となる基礎知識から最新の知見まで網羅した.

目次

  • I.脳卒中一次予防における降圧療法
     1 脳卒中一次予防における降圧療法
      1.脳卒中一次予防における血圧管理の重要性と高血圧パラドックス
      2.高血圧の診断と評価
      3.厳格降圧の有用性
      4.降圧管理の実際

    II.急性期治療における降圧療法
     1 総論(脳卒中の急性期降圧のエビデンス)
      1.脳梗塞
      2.脳出血
      3.くも膜下出血
     2 脳梗塞
      1.再灌流療法適応の場合
      2.再灌流療法非適応の場合
      3.発症前からの内服薬の継続の是非について
      4.どのような患者では早期降圧を検討すればよいか
     3 脳出血
      1.急性期の降圧療法
     4 くも膜下出血
      1.くも膜下出血の疫学
      2.SAHの急性期病態と臨床経過
      3.血圧管理の必要性
      4.再出血予防のための降圧
     5 動脈解離
      1.動脈解離の病態,病因,および疫学
      2.頭頸部動脈解離の分類
      3.頭頸部動脈解離急性期の血圧管理
     6 高血圧性脳症
      1.疾患概念
      2.病因
      3.病態
      4.病理
      5.画像所見
      6.高血圧性脳症の治療
      7.鑑別診断
      8.高血圧性脳症,PRES/RPLS,RCVSの位置づけ

    III.慢性期治療における降圧療法
     1 脳梗塞
      1.脳梗塞を含む脳卒中再発予防における降圧療法の有用性
      2.脳梗塞を含む脳卒中慢性期における降圧目標
      3.脳梗塞を含む脳卒中再発予防における降圧薬の選択
     2 脳出血とくも膜下出血
      1.脳出血の再発率
      2.慢性期脳出血の血圧管理
      3.脳出血の再発リスク
      4.慢性期脳出血の降圧治療に関するガイドライン
      5.慢性期くも膜下出血の血圧管理

    IV.無症候性病変への対応としての降圧療法
     1 無症候性脳梗塞
      1.定義
      2.診断
      3.疫学
      4.高血圧によるSBI
      5.治療
     2 大脳白質病変と脳出血
      1.大脳白質病変
      2.無症候性脳出血と脳微小出血
      3.大脳白質病変と脳微小出血
     3 血管性認知症
      1.血管性認知症の病態と臨床症状
      2.画像所見
      3.診断基準
      4.血管性認知症の治療
     4 無症候性頸部・頭蓋内血管狭窄
      1.降圧療法と脳循環
      2.脳主幹動脈閉塞症例の脳循環
      3.無症候性頸部頸動脈狭窄症例における血行再建術と薬物療法
      4.脳主幹動脈狭窄または閉塞症例における降圧療法後脳血流 
      5.降圧療法により有害事象をきたす症例
     5 未破裂脳動脈瘤
      1.未破裂脳動脈瘤の頻度
      2.未破裂脳動脈瘤の増大・新生
      3.未破裂脳動脈瘤の新たな検査
      4.未破裂脳動脈瘤の破裂危険因子と高血圧
      5.未破裂脳動脈瘤の治療成績
      6.未破裂脳動脈瘤への対応
      7.未破裂脳動脈瘤の原因

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 脳卒中一次予防における降圧療法

P.19 掲載の参考文献
1) McMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure : prospective observational studies corrected for regression dilution bias. Lancet. 1990 ; 335 : 765-74.
2) SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of Intensive versus standard blood?pressure control. N Engl J Med. 2015 ; 373 : 2103-16.
3) Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 ; 71 : e13-e115.
4) Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 ; 39 : 3021-104.
5) 日本高血圧学会. 高血圧治療ガイドライン 2019. 東京 : ライフサイエンス出版 ; 2019.
6) 厚生労働省. 平成28年度国民健康・栄養調査データ.
7) Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement : a population-based observation in Ohasama, Japan. J Hypertens. 1998 ; 16 : 971-5.
8) Niiranen TJ, Hanninen MR, Johansson J, et al. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure : The Finn-Home Study. Hypertension. 2010 ; 55 : 1346-51.
9) Kario K, Saito I, Kushiro T, et al. Morning home blood pressure is a strong predictor of coronary artery disease : The HONEST Study. J Am Coll Cardiol. 2016 ; 67 : 1519-27.
10) Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressure compared with office blood pressure in the general population : follow-up results from the Pression Arteriose Monitorate e Loro Assocoazioni (PAMELA) study. Circulation. 2005 ; 111 : 1777-83.
11) Boggia J, Li Y, Thijs L, et al, International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure : a cohort study. Lancet. 2007 ; 370 : 1219-29.
12) Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med. 2018 ; 378 : 1509-20.
13) Kario K, Pickering TG, Matsuo T, et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001 ; 38 : 852-7.
14) Kario K, Kanegae H, Tomitani N, et al. Nighttime blood pressure measured by home blood pressure monitoring as an independent predictor of cardiovascular events in general practice. Hypertension. 2019 ; 73 : 1240-8.
15) Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989 ; 79 : 733-43.
16) Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives : a prospective study. Circulation. 2003 ; 107 : 1401-6.
17) Li Y, Thijs L, Hansen TW, et al. International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension. 2010 ; 55 : 1040-8.
18) Kario K. Essential Mannual of 24-hour Blood Pressure Management from Morning to Nocturnal Hypertension. London : Wiley-Blackwell ; 2015.
19) Kario K, Shimada K, Schwartz JE, et al. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol. 2001 ; 38 : 238-45.
20) Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004 ; 291 : 1342-9.
21) Fujiwara T, Yano Y, Hoshide S, et al. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a Japanese general practice population. JAMA Cardiology. 2018 ; 3 : 583-90.
22) Narita K, Hoshide S, Kario K. Lowering the systolic blood pressure target in hypertensive patients : current controversies and future outlook. Expert Rev Cardiovasc Ther. 2018 ; 16 : 889-95.
24) Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality. JAMA Cardiol. 2017 ; 2 : 775-81.
25) Kario K, Wang JG. Could 130/80 mmHg be adapted as the diagnostic threshold and management goal of hypertension in consideration of the characteristics of Asian populations? Hypertension. 2018 ; 71 : 979-84.
26) Shimada K, Kario K, Kushiro T, et al. Prognostic significance of on-treatment home and clinic blood pressure for predicting cardiovascular events in hypertensive patients in the HONEST study. J Hypertens. 2016 ; 34 : 1520-7.
27) Messerli FH, Bangalore S, Bavishi C, et al. Angiotensin-converting enzyme inhibitors in hypertension : to use or not to use? J Am Coll Cardiol. 2018 ; 71 : 1474-82.
28) Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2) : a randomized, double-blind, crossover trial. Lancet. 2015 ; 386 : 2059-68.

II. 急性期治療における降圧療法

P.31 掲載の参考文献
1) Waklgren NG, MacMahon DG, De Keyser J, et al. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis. 1994 ; 4 : 204-10.
2) Schrader J, Luders S, Kulschewski A, et al. The ACCESS study : evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS). Stroke. 2003 ; 34 : 1699-703.
3) Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST) : a randmised, placebo-controlled, double-blind trial. Lancet. 2011 ; 377 : 741-50.
4) Liu Shuping, Li Chengyan, Li Tao, et al. Effects of early hypertension control after ischaemic stroke on the outcome : a meta-analysis. Cerebrovasc Dis. 2015 ; 40 : 270-8.
5) Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early ischemic stroke : meta-analysis. Stroke. 2015 ; 46 : 1883-9.
6) Yamamoto Y, Nagakane Y, Ohara T, et al. Intensive blood pressure-lowering treatment in patients with acute lacunar infarction. J Stroke Cerebrovasc Dis. 2013 ; 22 : 1273-8.
7) Robinson TG, Potter JF, Ford GA, et al. COSSACS Investigators. Effect of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS) : a prospective, randomized, open, blinded-endpoint trial. Lancet Neurol. 2010 ; 9 : 767-75.
8) Powers WJ, Rabinstein AA, Ackerson T, et al ; American Heart Association Stroke Council. 2018 guideline for the early management of patients with acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 ; 49 : e46-e110.
10) Yong M, Diener HC, Kaste M, et al. Long-term outcome as function of blood pressure in acute ischemic stroke and effects of thrombolysis. Cerebrovasc Dis. 2007 ; 24 : 349-54.
11) Andersen CS, Heeley E, Huang Y, et al ; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracranial hemorrhage. N Engl J Med. 2013 ; 368 : 2355-65.
12) Qureshi AI, Palesch YY, Barsan WG, et al ; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016 ; 375 : 1033-43.
13) Toyoda K, Koga M, Yamamoto H, et al. Clinical outcomes depending on acute blood pressure after cerebral hemorrhage. Ann Neurol. 2019 ; 85 : 105-13.
14) Butcher KS, Jeerakathil T, Hill M, et al ; ICH ADAPT Investigators. The intracerebral hemorrhage acutely decreasing arterial pressure trial. Stroke. 2013 ; 44 : 620-6.
15) Connolly ES, Rabinstein AA, Carhuapoma JR, et al ; American Heart Association Stroke Council. Guidelines for the management of aneurysmal subarachnoid hemorrhage : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012 ; 43 : 1711-37.
16) Tanno Y, Homma M, Kodama N, et al. Rebleeding from ruptured intracranial aneurysms in north eastern province of Japan. A cooperative study. J Neurol Sci. 2007 ; 258 : 11-6.
P.42 掲載の参考文献
1) 日本高血圧学会. 高血圧治療ガイドライン 2019. 東京 ; ライフサイエンス出版 ; 2019.
3) 黒田淳哉, 井林雪郎. 脳卒中予防における厳格な血圧管理の重要性. 血管医学. 2006 ; 7 : 161-8.
4) 日本脳卒中学会. 脳卒中治療ガイドライン 2015 [追補 2019]. 東京 ; 協和企画 ; 2019.
5) Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 ; 49 : e46-e110.
6) Yong M, Diener HC, Kaste M, et al. Long-term outcome as function of blood pressure in acute ischemic stroke and effects of thrombolysis. Cerebrovasc Dis. 2007 ; 24 : 349-54.
10) Albers GW, Lansberg MG, Kemp S, et al. A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3). Int J Stroke. 2017 ; 12 : 896-905.
11) Jovin TG, Saver JL, Ribo M, et al. Diffusion-weighted imaging or computerized tomography perfusion assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing neurointervention with Trevo (DAWN) trial methods. Int J Stroke. 2017 ; 12 : 641-52.
12) Maier B, Fahed R, Khoury N, et al. Association of blood pressure during thrombectomy for acute ischemic stroke with functional outcome : a systematic review. Stroke. 2019 ; 50 : 2805-12.
13) Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early ischemic stroke : meta-analysis. Stroke. 2015 ; 46 : 1883-9.
14) Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev. 2014 ; 2014 : CD000039.
16) He J, Zhang Y, Xu T, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke : the CATIS randomized clinical trial. JAMA. 2014 ; 311 : 479-89.
P.50 掲載の参考文献
1) Qureshi AI. Antihypertensive treatment of acute cerebral hemorrhage (ATACH) : rationale and design. Neurocrit Care. 2007 ; 6 : 56-66.
2) van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin : a systematic review and meta-analysis. Lancet Neurol. 2010 ; 9 : 167-76.
3) Maruishi M, Shima T, Okada Y, et al. Involvement of fluctuating high blood pressure in the enlargement of spontaneous intracerebral hematoma. Neurol Med Chir (Tokyo). 2001 ; 41 : 300-4 ; discussion 304-5.
5) Kazui S, Hiroaki N, Yamamoto H, et al. Enlargement of spontaneous intracerebral hematoma. Stroke. 1996 ; 27 : 1783-7.
6) Kazui S, Minematsu K, Yamamoto H, et al. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke. 1997 ; 28 : 2370-5.
7) Anderson CS, Huang Y, Arima H, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT) : a randomized pilot trial. Lancet Neurol. 2008 ; 7 : 391-9.
9) Qureshi AI, Palsech YY, Barsan WG, et al. Intensive blood pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016 ; 375 : 1033-43.
10) Toyoda K, Koga M, Yamamoto H, et al. Clinical outcomes depending on acute blood pressure after cerebral hemorrhage. Ann Neurol. 2019 ; 85 : 105-13.
11) Lattanzi S, Cagnetti C, Silvestrini M, et al. How should we lower blood pressure after cerebral hemorrhage? A systematic review and meta-analysis. Cerebrovasc Dis. 2017 ; 43 : 207-13.
12) Boulouis G, Morotti A, Goldstein JN, et al. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage : clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomized trials. J Neurol Neurosurg Psychiatry. 2017 ; 88 : 339-45.
13) Butcher KS, Jeerakathil T, Hill M, et al. The intraserebral hemorrhage acutely decreesing arterial pressure trial. Stroke. 2013 ; 44 : 620-6.
14) Antihypertensive Treatment of Acute Cerebral Hemorrage (ATACH) Investigators. Antihypertensive treatment of acute cerebral hemorrage. Crit Care Med. 2010 ; 38 : 637-48.
15) Koga M, Toyoda K, Naganuma M, et al. Nationwide survey of antihypertensive treatment for acute intracerebral hemorrhage in Japan. Hypertense Res. 2009 ; 32 : 759.
16) Koga M, Toyoda K, Yamagami H, et al. For Acute Management with Urgent Risk-factor Assesment and Improvement (SAMURAI) Study Investigators. Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage : a prospective, multicenter, observantional study. J Hypertens. 2012 ; 30 : 2357-64.
P.67 掲載の参考文献
1) Ohkuma H, Fujita, Suzuki S. Incidence of aneurysmal subarachnoid hemorrhage in Shimokita, Japan, from 1989 to 1998. Stroke. 2002 ; 33 : 195-9.
2) Morita A, Kirino T, Hashi K, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med. 2012 ; 366 : 2474-82.
3) Sonobe M, Yamazaki T, Yonekura M, et al. Small unruptured intracranial aneurysm verification study : SUAVe study, Japan. Stroke. 2010 ; 41 : 1969-77.
4) Dubosh NM, Bellolio MF, Rabinstein AA, et al. Sensitivity of early brain computed tomography to exclude aneurysmal subarachnoid hemorrhage : a systematic review and meta-analysis. Stroke. 2016 ; 47 : 750-5.
5) 石井暁. 脳動脈瘤の血管内治療の現状と近未来. 脳外誌. 2020 ; 29 : 94-100.
6) Macdonald RL, Kassell NF, Mayer S. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1) : randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008 ; 39 : 3015-21.
7) Lu VM, Graffeo CS, Perry A, et al. Rebleeding drives poor outcome in aneurysmal subarachnoid hemorrhage independent of delayed cerebral ischemia : a propensity-score matched cohort study. J Neurosurg. 2019 ; 19 : 1-9.
8) Galea JP, Dulhanty L, Patel HC, et al. Predictors of outcome in aneurysmal subarachnoid hemorrhage patients : observations from a multicenter data set. Stroke. 2017 ; 48 : 2958-63.
9) Kassell NF, Torner JC. Aneurysmal rebleeding : a preliminary report from the Cooperative Aneurysm Study. Neurosurgery. 1983 ; 13 : 479-81.
10) Tang C, Zhang TS, Zhou LF. Risk factors for rebleeding of aneurysmal subarachnoid hemorrhage : a meta-analysis. PLoS One. 2014 ; 9 : e99536.
11) Ando T, Sakai N, Yamada H, et al. Analysis of reruptured cerebral aneurysms and the prophylactic effects of barbiturate therapy on the early stage. Neurol Res. 1989 ; 11 : 245-8.
12) Fujii Y, Takeuchi S, Sasaki O, et al. Ultra-early rebleeding in spontaneous subarachnoid hemorrhage. J Neurosurg. 1996 ; 84 : 35-42.
13) Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke. 2001 ; 32 : 1176-80.
14) Tanno Y, Homma M, Oinuma M, et al. Rebleeding from ruptured intracranial aneurysms in North Eastern Province of Japan. A cooperative study. J Neurol Sci. 2007 ; 258 : 11-6.
15) Guo LM, Zhou HY, Xu JW, et al. Risk factors related to aneurysmal rebleeding. World Neurosurg. 2011 ; 76 : 253-4, 292-8.
16) van Donkelaar CE, Bakker NA, Veeger NJ, et al. Predictive factors for rebleeding after aneurysmal subarachnoid hemorrhage : rebleeding aneurysmal subarachnoid hemorrhage study. Stroke. 2015 ; 46 : 2100-6.
17) Inagawa T, Kamiya K, Ogasawara H, et al. Rebleeding of ruptured intracranial aneurysms in the acute stage. Surg Neurol. 1987 ; 28 : 93-9.
18) Oheda M, Inamasu J, Moriya S, et al. Early rebleeding in patients with subarachnoid haemorrhage under intensive blood pressure management. J Clin Neurosci. 2015 ; 22 : 1338-42.
19) Cong W, Zhongxin Z, Tiangui L, et al. Risk factors for rebleeding of aneurysmal subarachnoid hemorrhage based on the analysis of on-admission information. Turk Neurosurg. 2012 ; 22 : 675-81.
20) Solanki C, Pandey P, Rao KV, et al. Predictors of aneurysmal rebleed before definitive surgical or endovascular management. Acta Neurochir (Wien). 2016 ; 158 : 1037-44.
21) Lin QS, Ping-Chen, Lin YX, et al. Systolic blood pressure variability is a novel risk factor for rebleeding in acute subarachnoid hemorrhage : a case-control study. Medicine (Baltimore). 2016 ; 95 : e3028.
22) L iu-Deryke X, Janisse J, Coplin WM, et al. A comparison of nicardipine and labetalol for acute hypertension management following stroke. Neurocrit Care. 2008 ; 9 : 167-76.
23) Roitberg BZ, Hardman J, Urbaniak K, et al. Prospective randomized comparison of safety and efficacy of nicardipine and nitroprusside drip for control of hypertension in the neurosurgical intensive care unit. Neurosurgery. 2008 ; 63 : 115-21.
P.80 掲載の参考文献
1) Zweifler RM, Silverboard G. Chapter 35, Arterial dissections and fibromuscular dysplasia. In : Grotta J, et al. editors. Stroke : Pathophysiology, Diagnosis, and Management, 6th ed. Elsevier ; 2016. p.599-618. e7.
2) 松岡秀樹. 3. 脳動脈解離の現状, (2) 本邦の実態. In : 峰松一夫. 循環器研究委託費18 公-5 (SCADS-Japan) 脳血管解離の病態と治療法の開発 脳動脈診療の手引き. 大阪 : 国立循環器病センター脳血管部門 ; 2009. p.8-16.
3) Biller J, Sacco RL, Albuquerque FC, et al. Cervical arterial dissections and association with cervical manipulative therapy. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 ; 45 : 3155-74.
4) Velat GJ, Hoh BL, Ogilvy CS. Chapter 67, Management of dissections of the carotid and vertebral arteries. In : Quinones-Hinojosa. Schmidek and Sweet's Operative Neurosurgical Techniques, 6th ed. Elsevier ; 2012. p.806-11.
5) 高木誠. 脳動脈解離の (Cerebral arterial dissection) の診断と治療の手引き. In : 峰松一夫. 循環器病研究委託費12 指-2 若年世代の脳卒中の診断, 治療, 予防戦略に関する全国多施設共同研究. 大阪 : 国立循環器病センター脳血管部門 ; 2003. p.85-90.
6) 脳卒中超急性期の呼吸・循環・代謝管理 (2) 血圧, 頭蓋内・外動脈解離の内科的治療. In : 日本脳卒中学会. 脳卒中治療ガイドライン 2015 [追補 2019]. 東京 : 協和企画 ; 2019. p.6-7, p.244-5.
7) 臓器障害を合併する高血圧 1. 脳血管障害. In : 日本高血圧学会. 高血圧治療ガイドライン 2019. 東京 : ライフサイエンス出版 ; 2019. p.94-123.
8) Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute Ischemic stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 ; 49 : e46-e99.
9) Schrader J, Luders S, Kulschewski A, et al. The ACCESS study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003 ; 34 : 1699-703.
10) Sandset EC, Bath PMW, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST) : a ran-domised, placebo-controlled, double-blind trial. Lancet. 2011 ; 377 : 741-50.
11) Connolly, Jr ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012 ; 43 : 1711-37.
P.92 掲載の参考文献
1) Oppenheimer BS, Fishberg AM. Hypertensive encephalopathy. Arch Intern Med (Chic). 1928 ; 41 : 264-78.
3) Healton EB, Brust JC, Feinfeld DA, et al. Hypertensive encephalopathy and the neurologic manifestations of malignant hypertension. Neurology. 1982 ; 32 : 127-32.
4) Weingarten K, Barbut D, Filippi CG, et al. Acute hypertensive encephalopathy : findings on spin-echo and gradient-echo MR imaging. AJR Am J Roentgenol. 1994 ; 162 : 665-70.
5) Chester EM, Agamanolis DP, Banker BQ, et al. Hypertensive encephalopathy : a clinicopathologic study of 20 cases. Neurology. 1978 ; 28 : 928-39.
6) Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy : findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol. 1992 ; 159 : 379-83.
8) Casey SO, Sampaio RC, Michel E, et al. Posterior reversible encephalopathy syndrome : utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol. 2000 ; 21 : 1199-206.
9) 伊藤康広, 近藤直英, 加藤みのり, 他. Reversible posterior leukoencephalopathy syndromeの疾患概念. 神経内科. 2005 ; 63 : 307-22.
10) Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012 ; 11 : 906-17.

III. 慢性期治療における降圧療法

P.105 掲載の参考文献
1) Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010 : findings from the Global Burden of Disease Study 2010. Lancet. 2014 ; 383 : 245-54.
2) Arima H, Tzourio C, Butcher K, et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke. 2006 ; 37 : 1497-502.
3) Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events : results of prospectively-designed overviews of randomised trials. Lancet. 2003 ; 362 : 1527-35.
4) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001 ; 358 : 1033-41.
6) Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl). 1995 ; 108 : 710-7.
7) Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke. 1997 ; 28 : 2557-62.
8) Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history : the PROGRESS trial. Stroke. 2004 ; 35 : 116-21.
9) Berthet K, Neal BC, Chalmers JP, et al. Reductions in the risks of recurrent stroke in patients with and without diabetes : the PROGRESS trial. Blood Press. 2004 ; 13 : 7-13.
12) Arima H, Anderson C, Omae T, et al. Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease : the PROGRESS trial. J Hypertens. 2010 ; 28 : 395-400.
14) Mant J, McManus RJ, Roalfe A, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack : PAST-BP (Prevention After Stroke-Blood Pressure) randomised controlled trial. BMJ. 2016 ; 352 : i708.
15) Bath PM, Scutt P, Blackburn DJ, et al. Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke : main results from the pilot'Prevention of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial. PLoS One. 2017 ; 12 : e0164608.
16) Kitagawa K, Yamamoto Y, Arima H, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke : a randomized clinical trial and meta-analysis. JAMA Neurol. 2019 ; 76 : 1309-18.
17) Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 ; 71 : 1269-324.
18) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Rev Esp Cardiol (Engl Ed). 2019 ; 72 : 160.
19) 日本高血圧学会. 高血圧治療ガイドライン 2019. 東京 : ライフサイエンス出版 ; 2019.
20) Turan TN, Cotsonis G, Lynn MJ, et al. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation. 2007 ; 115 : 2969-75.
21) Rothwell PM, Howard SC, Spence JD. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke. 2003 ; 34 : 2583-90.
22) Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention : principal results of a prospective randomized controlled study (MOSES). Stroke. 2005 ; 36 : 1218-26.
23) Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial : outcomes in patients receiving monotherapy. Hypertension. 2006 ; 48 : 385-91.
24) Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks : candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008 ; 51 : 393-8.
P.115 掲載の参考文献
1) Hata J, Ninomiya T, Hirakawa Y, et al. Secular trends in cardiovascular disease and its risk factors in Japanese : Half-century data from the Hisayama study (1961-2009). Circulation. 2013 ; 128 : 1198-205.
2) Hata J, Tanizaki Y, Kiyohara Y, et al. Ten year recurrence after first ever stroke in a Japanese community : the Hisayama study. J Neurol Neurosurg Psychiatry. 2005 ; 76 : 368-72.
3) Arima H, Tzourio C, Butcher K, et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke. 2006 ; 37 : 1497-502.
5) Arakawa S, Saku Y, Ibayashi S, et al. Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke. 1998 ; 29 : 1806-9.
6) Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history : the PROGRESS trial. Stroke. 2004 ; 35 : 116-21.
8) Jeon SB, Kang DW, Cho AH, et al. Initial microbleeds at MR imaging can predict recurrent intracerebral hemorrhage. J Neurol. 2007 ; 254 : 508-12.
11) O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000 ; 342 : 240-5.
12) Arima H, Tzourio C, Anderson C, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy : the PROGRESS trial. Stroke. 2010 ; 41 : 394-6.
13) Wakisaka Y, Miller JD, Chu Y, et al. Oxidative stress through activation of NAD (P) H oxidase in hypertensive mice with spontaneous intracranial hemorrhage. J Cereb Blood Flow Metab. 2008 ; 28 : 1175-85.
14) Kumai Y, Ooboshi H, Ago T, et al. Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure. Exp Neurol. 2008 ; 210 : 441-8.
15) Kitagawa K, Yamamoto Y, Arima H, et al. Effect of standard vs intensive blood pressure control on the risk of recurrent stroke : a randomized clinical trial and meta-analysis. JAMA Neurol. 2019 ; doi : 10.1001/jamaneurol.2019.2167.
16) Biffi A, Anderson CD, Battey TWK, et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA. 2015 ; 314 : 904-12.
17) Etina N, Baseoglu K, Steiger HJ, et al. The impact of hypertension and nicotine on the size of ruptured intracranial aneurysms. J Neurol Neurosurg Psychiatry. 2011 ; 82 : 4-7.
18) Greving JP, Wermer MJ, Brown RD, et al. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms : a pooled analysis of six prospective cohort studies. Lancet Neurol. 2014 ; 13 : 59-66.
19) Wermer MJ, van der Schaaf IC, Velthuis BK, et al. Follow-up screening after subarachnoid haemorrhage : frequency and determinants of new aneurysms and enlargement of existing aneurysms. Brain. 2005 ; 128 : 2421-9.
20) Bor AS, Tiel Groenestege AT, terBrugge KG, et al. Clinical, radiological, and flow-related risk factors for growth of untreated, unruptured intracranial aneurysms. Stroke. 2015 ; 46 : 42-8.
21) Backers D, Rinkel GJ, Laben KG, et al. Patient- and aneurysm-specific risk factors for intracranial aneurysm growth. A systematic review and meta-analysis. Stroke. 2016 ; 47 : 951-7.

IV. 無症候性病変への対応としての降圧療法

P.127 掲載の参考文献
1) Gupta A, Giambrone AE, Gialdini G, et al. Silent brain infarction and risk of future stroke : a systematic review and meta-analysis. Stroke. 2016 ; 47 : 719-25.
2) Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 ; 12 : 822-38.
4) Kase CS, Wolf PA, Chodosh EH, et al. Prevalence of silent stroke in patients presenting with initial stroke : the Framingham Study. Stroke. 1989 ; 20 : 850-2.
5) Bernick C, Kuller L, Dulberg C, et al. Silent MRI infarcts and the risk of future stroke : the cardiovascular health study. Neurology. 2001 ; 57 : 1222-9.
6) Windham BG, Deere B, Griswold ME, et al. Small brain lesions and incident stroke and mortality : a cohort study. Ann Intern Med. 2015 ; 163 : 22-31.
7) Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality : the Framingham Offspring Study. Stroke. 2010 ; 41 : 600-6.
8) Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction : a systematic review of population-based cohorts. BMC Med. 2014 ; 12 : 119.
9) Scuteri A, Nilsson PM, Tzourio C, Redon J, Laurent S. Microvascular brain damage with aging and hypertension : pathophysiological consideration and clinical implications. J Hypertens. 2011 ; 29 : 1469-77.
10) Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004 ; 5 : 347-60.
11) Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol. 2006 ; 100 : 1059-64.
12) Cauli B, Hamel E. Revisiting the role of neurons in neurovascular coupling. Front Neuroenergetics. 2010 ; 2 : 9.
13) D'Esposito M, Deouell LY, Gazzaley A. Alterations in the BOLD fMRI signal with ageing and disease : a challenge for neuroimaging. Nat Rev Neurosci. 2003 ; 4 : 863-72.
14) Andresen J, Shafi NI, Bryan RM. Endothelial influences on cerebrovascular tone. J Appl Physiol. 2006 ; 100 : 318-27.
15) Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003 ; 111 : 1201-9.
16) Parsons KK, Coffman TM. The renin-angiotensin system : it's all in your head. J Clin Invest. 2007 ; 117 : 873-6.
17) Capone C, Faraco G, Park L, et al. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol. 2011 ; 300 : H397-407.
18) Hasegawa Y, Yamaguchi T, Omae T, et al. Effects of perindopril-based blood pressure lowering and of patient characteristics on the progression of silent brain infarct : the perindopril protection against recurrent stroke study (PROGRESS) CT substudy in Japan. Hypertens Res. 2004 ; 27 : 147-56.
19) Shinohara Y, Tohgi H, Hirai S, et al. Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA study) : 1. Design and results at enrollment. Cerebrovasc Dis. 2007 ; 24 : 202-9.
20) Maestrini I, Altieri M, Di Clemente L, et al. Longitudinal study on low-dose aspirin versus placebo administration in silent brain infarcts : the silence study. Stroke Res Treat. 2018 ; 2018 : 7532403.
21) Smith EE, Saposnik G, Biessels GJ, et al. Prevention of stroke in patients with silent cerebrovascular disease : a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017 ; 48 : e44-e71.
P.139 掲載の参考文献
1) Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 ; 12 : 822-38.
2) Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987 ; 149 : 351-6.
3) Etherton MR, Wu O, Rost NS. Recent advances in leukoaraiosis : white matter structural integrity and functional outcomes after acute ischemic stroke. Curr Cardiol Rep. 2016 ; 18 : 123.
4) Moroni F, Ammirati E, Rocca MA, et al. Cardiovascular disease and brain health : Focus on white matter hyperintensities. Int J Cardiol Heart Vasc. 2018 ; 19 : 63-9.
5) Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 ; 71 : 2199-269.
6) Nam KW, Kwon HM, Jeong HY, et al. Cerebral small vessel disease and stage 1 hypertension defined by the 2017 American College of Cardiology/American Heart Association Guidelines. Hypertension. 2019 ; 73 : 1210-6.
7) Henskens LH, Kroon AA, van Oostenbrugge RJ, et al. Associations of ambulatory blood pressure levels with white matter hyperintensity volumes in hypertensive patients. J Hypertens. 2009 ; 27 : 1446-52.
8) Gottesman RF, Coresh J, Catellier DJ, et al. Blood pressure and white-matter disease progression in a biethnic cohort : Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2010 ; 41 : 3-8.
9) Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality : the Framingham Offspring Study. Stroke. 2010 ; 41 : 600-6.
10) Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging : systematic review and meta-analysis. BMJ. 2010 ; 341 : c3666.
11) Folsom AR, Yatsuya H, Mosley TH, et al. Risk of intraparenchymal hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. Ann Neurol. 2012 ; 71 : 552-9.
12) Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke. 1996 ; 27 : 2262-70.
13) Ferreira JP, Kearney Schwartz A, et al. Memory alterations and white matter hyperintensities in elderly patients with hypertension : the ADELAHYDE-2 Study. J Am Med Dir Assoc. 2017 ; 18 : 451, e413-451, e425.
14) 藥師寺祐介, 吉川正章, 相島慎一. 無症候性脳出血と微小脳出血の臨床的意義. In : 田川皓一, 他編. マスター脳卒中学. 東京 : 西村書店 ; 2019. p.482-9.
15) Yakushiji Y. Cerebral microbleeds : detection, associations, and clinical implications. Front Neurol Neurosci 2016 ; 37 : 78-92.
16) Yakushiji Y, Yokota C, Yamada N, et al. Clinical characteristics by topographical distribution of brain microbleeds, with a particular emphasis on diffuse microbleeds. J Stroke Cerebrovasc Dis. 2011 ; 20 : 214-21.
17) Yakushiji Y, Werring DJ. Cerebrovascular disease : Lobar cerebral microbleeds signal early cognitive impairment. Nat Rev Neurol. 2016 ; 12 : 680-2.
18) Yakushiji Y, Wilson D, Ambler G, et al. Distribution of cerebral microbleeds in the East and West : Individual participant meta-analysis. Neurology. 2019 ; 92 : e1086-e1097.
19) Bokura H, Saika R, Yamaguchi T, et al. Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke 2011 ; 42 : 1867-71.
20) Akoudad S, Portegies ML, Koudstaal PJ, et al. Cerebral microbleeds are associated with an increased risk of stroke : the Rotterdam study. Circulation. 2015 ; 132 : 509-16.
21) Shoamanesh A, Pearce LA, Bazan C, et al. Microbleeds in the secondary prevention of small subcortical strokes trial : stroke, mortality, and treatment interactions. Ann Neurol. 2017 ; 82 : 196-207.
23) Poels MM, Ikram MA, van der Lugt A, et al. Incidence of cerebral microbleeds in the general population : the Rotterdam Scan Study. Stroke 2011 ; 42 : 656-61.
24) Shoamanesh A, Morotti A, Romero JM, et al. Cerebral microbleeds and the effect of intensive blood pressure reduction on hematoma expansion and functional outcomes : a secondary analysis of the ATACH-2 randomized clinical trial. JAMA Neurology. 2018 ; 75 : 850-9.
25) Yakushiji Y, Charidimou A, Noguchi T, et al. Total small vessel disease score in neurologically healthy Japanese adults in the Kashima scan study. Intern Med. 2018 ; 57 : 189-96.
26) 発見される代表的な異常とその対策. In : 日本脳ドック学会. 脳ドックのガイドライン 2019 [改訂・第5版]. 札幌市 : 響文社 ; 2019. p.47-52.
P.154 掲載の参考文献
2) Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia : how to move forward? Neurology. 2009 ; 72 : 368-74.
3) Chui, H. Vascular dementia, a new beginning : shifting focus from clinical phenotype to ischemic brain injury. Neurol Clin. 2000 ; 18 : 951-78.
5) Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 ; 12 : 822-38.
7) Association AP. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC : American Psychiatric Pub ; 2013.
8) Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders : a VASCOG statement. Alzheimer Dis Assoc Disord. 2014 ; 28 : 206-18.
10) Gold G, Giannakopoulos P, Montes-Paixao Junior C, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology. 1997 ; 49 : 690-4.
11) Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol. 2010 ; 7 : 686-98.
12) Ninomiya T, Ohara T, Hirakawa Y, et al. Midlife and late-life blood pressure and dementia in Japanese elderly : the Hisayama study. Hypertension. 2011 ; 58 : 22-8.
13) Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 ; 352 : 1347-51.
14) Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003 ; 163 : 1069-75.
15) SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, et al. Effect of intensive vs standard blood pressure control on probable dementia : a randomized clinical trial. JAMA. 2019 ; 321 : 553-61.
16) Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG) : a double-blind, placebo controlled trial. Lancet Neurol. 2008 ; 7 : 683-9.
17) Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition : a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013 ; 88 : 1213-21.
18) Anstey KJ, von Sanden C, Salim A, et al. Smoking as a risk factor for dementia and cognitive decline : a meta-analysis of prospective studies. Am J Epidemiol. 2007 ; 166 : 367-78.
19) Douiri A, McKevitt C, Emmett ES, et al. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation. 2013 ; 128 : 1341-8.
20) Jacobs V, Woller SC, Stevens S, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm. 2014 ; 11 : 2206-13.
21) Jacobs V, May HT, Bair TL, et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol. 2016 ; 118 : 210-4.
22) Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004 ; (1) : CD004395.
23) Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia : a randomized trial. Neurology. 2007 ; 69 : 448-58.
24) Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev. 2006 ; (1) : CD004746.
25) Birks J, McGuinness B, Craig D, Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev. 2013 ; (5) : CD004744.
26) Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia : a randomized, placebo-controlled trial (MMM 300). Stroke. 2002 ; 33 : 1834-9.
27) Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 ; 17 : 297-305.
28) Bes A, Orgogozo JM, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol. 1999 ; 6 : 313-22.
29) von Gunten A, Schlaefke S, Uberla K. Efficacy of Ginkgo biloba extract EGb 761R in dementia with behavioral and psychological symptoms : a systematic review. World J Biol Psychiatry. 2016 ; 17 : 622-33.
30) Liu-Ambrose T, Best JR, Davis JC, et al. Aerobic exercise and vascular cognitive impairment : a randomized controlled trial. Neurology. 2016 ; 87 : 2082-90.
31) Steffens DC, Chung H, Krishnan KR, et al. Antidepressant treatment and worsening white matter on serial cranial magnetic resonance imaging in the elderly : the Cardiovascular Health Study. Stroke. 2008 ; 39 : 857-62.
32) Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry. 2005 ; 66 : 248-52.
33) Nagata K, Yokoyama E, Yamazaki T, et al. Effects of yokukansan on behavioral and psychological symptoms of vascular dementia : an open-label trial. Phytomedicine. 2012 ; 19 : 524-8.
34) Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003 ; 64 : 134-43.
P.165 掲載の参考文献
1) Ruland S, Aiyagari V. Cerebral autoregulation and blood pressure lowering. Hypertension. 2007 ; 49 : 977-8.
2) James IM, Yogendran L, McLaughlin K, et al. Blood pressure lowering and cerebral blood flow : a comparison of the effects of carvedilol and propranolol on the cerebral circulation in hypertensive patients. J Cardiovasc Pharmacol. 1992 ; 19 Suppl 1 : S40-43.
3) Strandgaard S, Paulson OB. Regulation of cerebral blood flow in health and disease. J Cardiovasc Pharmacol. 1992 ; 19 Suppl 6 : S89-93.
4) Ogasawara K, Ogawa A [. Jet study (Japanese ec-ic bypass trial) ]. Nihon Rinsho. 2006 ; 64 Suppl 7 : 524-7.
5) Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010 ; 363 : 11-23.
6) Halliday A, Harrison M, Hayter E, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (acst-1) : a multicentre randomised trial. Lancet. 2010 ; 376 : 1074-84.
8) de Waard DD, de Borst GJ, Bulbulia R, et al ; Asymptomatic Carotid Surgery Trial-1 Collaborative Group. Diastolic blood pressure is a risk factor for peri-procedural stroke following carotid endarterectomy in asymptomatic patients. Eur J Vasc Endovasc Surg. 2017 ; 53 : 626-31.
9) Jusufovic M, Sandset EC, Bath PM, et al ; Scandinavian Candesartan Acute Stroke Trial Study Group. Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. Int J Stroke. 2015 ; 10 : 354-9.
10) Jusufovic M, Sandset EC, Skagen K, et al. Blood pressure lowering treatment in patients with carotid artery stenosis. Curr Hypertens Rev. 2016 ; 12 : 148-55.
11) Sare GM, Gray LJ, Wardlaw J, et al. Is lowering blood pressure hazardous in patients with significant ipsilateral carotid stenosis and acute ischaemic stroke? Interim assessment in the 'efficacy of nitric oxide in stroke' trial. Blood Press Monit. 2009 ; 14 : 20-5.
12) Saura H, Ogasawara K, Suzuki T, et al. Effect of combination therapy with the angiotensin receptor blocker losartan plus hydrochlorothiazide on brain perfusion in patients with both hypertension and cerebral hemodynamic impairment due to symptomatic chronic major cerebral artery steno-occlusive disease : a spect study. Cerebrovasc Dis. 2012 ; 33 : 354-61.
13) Nagahama Y, Fukuyama H, Yamauchi H, et al. Effect of nicardipine on cerebral blood flow in hypertensive patients with internal carotid artery occlusion : a pet study. J Stroke Cerebrovasc Dis. 1997 ; 6 : 325-31.
14) Yamauchi H. Evidence for cerebral hemodynamic measurement-based therapy in symptomatic major cerebral artery disease. Neurol Med Chir (Tokyo). 2015 ; 55 : 453-9.
15) Yamauchi H, Kagawa S, Kishibe Y, et al. Misery perfusion, blood pressure control, and 5-year stroke risk in symptomatic major cerebral artery disease. Stroke. 2015 ; 46 : 265-8.
16) Fujimura M, Inoue T, Shimizu H, et al. Efficacy of prophylactic blood pressure lowering according to a standardized postoperative management protocol to prevent symptomatic cerebral hyperperfusion after direct revascularization surgery for moyamoya disease. Cerebrovasc Dis. 2012 ; 33 : 436-45.
17) Castaldo JE, Yacoub HA, Li Y, et al. Open heart surgery does not increase the incidence of ipsilateral ischemic stroke in patients with asymptomatic severe carotid stenosis. J Stroke Cerebrovasc Dis. 2017 ; 26 : 2154-9.
P.179 掲載の参考文献
1) Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period : a systematic review and meta-analysis. Lancet Neurol. 2011 ; 10 : 626-36.
2) Imaizumi Y, Mizutani T, Shimizu K, et al. Detection rates and sites of unruptured intracranial aneurysms according to sex and age : an analysis of MR angiography-based brain examinations of 4070 healthy Japanese adults. J Neurosurg. 2018 : 130 ; 573-8.
3) Chan DY, Abrigo JM, Cheung TC, et al. Screening for intracranial aneurysms? Prevalence of unruptured intracranial aneurysms in Hong Kong Chinese. J Neurosurg. 2016 ; 124 : 1245-9.
4) Wiebers DO. Unruptured intracranial aneurysms : natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003 ; 362 : 103-10.
5) Morita A, Kirino T, Hashi K, et al. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med. 2012 ; 366 : 2474-82.
7) Giordan E, Lanzino G, Rangel-Castilla L, et al. Risk of de novo aneurysm formation in patients with a prior diagnosis of ruptured or unruptured aneurysm : systematic review and meta-analysis. J Neurosurg. 2018 : 131 ; 14-24.
8) Hu S, Yu N, Li Y, et al. A meta-analysis of risk factors for the formation of de novo intracranial aneurysms. Neurosurgery. 2019 ; 85 : 454-65.
9) Backes D, Rinkel GJ, Laban KG, et al. Patient- and aneurysm-specific risk factors for intracranial aneurysm growth : a systematic review and meta-analysis. Stroke. 2016 ; 47 : 951-7.
10) Mocco J, Brown RD, Jr., Torner JC, et al. Aneurysm morphology and prediction of rupture : an international study of unruptured intracranial aneurysms analysis. Neurosurgery. 2018 ; 82 : 491-6.
11) Murayama Y, Takao H, Ishibashi T, et al. Risk analysis of unruptured intracranial aneurysms : prospective 10-year cohort study. Stroke. 2016 ; 47 : 365-71.
15) Can A, Du R. Association of hemodynamic factors with intracranial aneurysm formation and rupture : systematic review and meta-analysis. Neurosurgery. 2016 ; 78 : 510-20.
16) Greving JP, Wermer MJ, Brown RD Jr, et al. Development of the phases score for prediction of risk of rupture of intracranial aneurysms : a pooled analysis of six prospective cohort studies. Lancet Neurol. 2014 ; 13 : 59-66.
17) Tominari S, Morita A, Ishibashi T, et al. Prediction model for 3-year rupture risk of unruptured cerebral aneurysms in Japanese patients. Ann Neurol. 2015 ; 77 : 1050-9.
18) Sonobe M, Yamazaki T, Yonekura M, et al. Small unruptured intracranial aneurysm verification study : SUAVe study, Japan. Stroke. 2010 ; 41 : 1969-77.
19) Guresir E, Vatter H, Schuss P, et al. Natural history of small unruptured anterior circulation aneurysms : a prospective cohort study. Stroke. 2013 ; 44 : 3027-31.
20) Dolati P, Pittman D, Morrish WF, et al. The frequency of subarachnoid hemorrhage from very small cerebral aneurysms (< 5 mm) : a population-based study. Cureus. 2015 ; 7 : e279.
21) Ikawa F, Morita A, Tominari S, et al. Rupture risk of small unruptured cerebral aneurysms. J Neurosurg. 2019 ; 1-10. Online ahead of print.
22) Etminan N, Chang HS, Hackenberg K, et al. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population : a systematic review and meta-analysis. JAMA Neurol. 2019 ; 76 : 588-97.
23) Ikawa F, Morita A, Nakayama T, et al. A register-based SAH study in Japan : high incidence rate and recent decline trend based on life-style. J Neurosurg. 2020 ; 1-9. Online ahead of print. 24) Bekelis K, Gottlieb DJ, Su Y, et al. Comparison of clipping and coiling in elderly patients with unruptured cerebral aneurysms. J Neurosurg. 2017 ; 126 : 811-8.
25) Silva NA, Shao B, Sylvester MJ, et al. Unruptured aneurysms in the elderly : perioperative outcomes and cost analysis of endovascular coiling and surgical clipping. Neurosurg Focus. 2018 ; 44 : E4.
26) Dasenbrock HH, Smith TR, Rudy RF, et al. Reoperation and readmission after clipping of an unruptured intracranial aneurysm : a national surgical quality improvement program analysis. J Neurosurg. 2018 ; 128 : 756-67.
27) Ikawa F, Hidaka T, Yoshiyama M, et al. Characteristics of cerebral aneurysms in Japan. Neurologia medico-chirurgica. 2019 ; 59 : 399-406.
28) Ikawa F, Michihata N, Akiyama Y, et al. Treatment risk for elderly patients with unruptured cerebral aneurysm from a nationwide database in Japan. World Neurosurg. 2019 ; 132 : e89-e98.
29) Ikawa F, Michihata N, Akiyama Y, et al. Propensity score matching analysis for the patients of unruptured cerebral aneurysm from a post hoc analysis of nationwide database in Japan : propensity score matching analysis of uca. World Neurosurg. 2020 : 136 ; e371-e379.
30) Algra AM, Lindgren A, Vergouwen MDI, et al. Procedural clinical complications, case-fatality risks, and risk factors in endovascular and neurosurgical treatment of unruptured intracranial aneurysms : a systematic review and meta-analysis. JAMA Neurol. 2019 ; 76 : 282-93.
31) Zhang X, Tang H, Huang Q, et al. Total hospital costs and length of stay of endovascular coiling versus neurosurgical clipping for unruptured intracranial aneurysms : systematic review and meta-analysis. World Neurosurg. 2018 ; 115 : 393-9.
34) Bonares MJ, Egeto P, de Oliveira Manoel AL, et al. Unruptured intracranial aneurysm treatment effects on cognitive function : a meta-analysis. J Neurosurg. 2016 ; 124 : 784-90.
37) Malhotra A, Wu X, Forman HP, et al. Management of tiny unruptured intracranial aneurysms : a comparative effectiveness analysis. JAMA Neurol. 2018 ; 75 : 27-34.
38) Pawlowska E, Szczepanska J, Wisniewski K, et al. Nf-kappab-mediated inflammation in the pathogenesis of intracranial aneurysm and subarachnoid hemorrhage. Does autophagy play a role? Int J Mol Sci. 2018 ; 19 : 1245.

最近チェックした商品履歴

Loading...